المؤلفون: Zev A. Wainberg, Keun-Wook Lee, Inho Kim, Anwaar Saeed, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Daniel V.T. Catenacci, Raquel Guardeño, Christophe Borg, Siddhartha Mitra, Erika Hitre, Jin Li, Anghel Adrian Udrea, Yoon-Koo Kang, Kensei Yamaguchi, Yingsi Yang, Sang Cheul Oh, Shukui Qin, Peter C. Enzinger, Haci Mehmet Turk

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, medicine.drug_class, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Placebo, Monoclonal antibody, Gastroenterology, Double blind, Oncology, A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 [Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT], Internal medicine, Fibroblast Growth Factor Receptor 2b, Medicine, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84cd51b695b646eaa8b082749dbaa24
http://hdl.handle.net/20.500.12645/29666

المؤلفون: Keun-Wook Lee, Zev A. Wainberg, Yingsi Yang, Shukui Qin, Helen Collins, Haci Mehmet Turk, Siddhartha Mitra, Giovanni Gerardo Cardellino, Alexandra Carolina Teixeira, Yoon-Koo Kang, Sang Cheul Oh, Daniel V.T. Catenacci, Kensei Yamaguchi, Raquel Guardeño, Jin Li, Peter C. Enzinger

المساهمون: TÜRK, HACI MEHMET

المصدر: Journal of Clinical Oncology. 39:160-160

مصطلحات موضوعية: Cancer Research, medicine.drug_class, business.industry, First line, Phases of clinical research, Gastroesophageal Junction Adenocarcinoma, Pharmacology, Placebo, Monoclonal antibody, Double blind, Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, business, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dfff608f3c1c9cd07f54b7554dd6501
https://doi.org/10.1200/jco.2021.39.3_suppl.160